Home » News » Drug Sponsors » Teva purchases 51% equity share of Immuneering

Teva purchases 51% equity share of Immuneering

Wednesday, August 5, 2015

Jerusalem-based Teva Pharmaceutical Industries has entered into an agreement to purchase a 51% equity share of Immuneering, a Cambridge, Mass.-based genomic-analysis company. Immuneering uses advanced proprietary techniques to identify hidden signals and biological insights across an array of genetic, genomic, and proteomic data that can direct research for enhanced discovery, development and clinical success.

Teva and Immuneering have worked together over the past several years to unlock genetic biomarkers, therapy-specific gene expression signatures and characterizing non-biological complex drugs (NBCDs). Teva’s majority holding in Immuneering provides right of first refusal in projects relating to the company’s stated objective of developing, personalizing and improving treatment of disorders of the central nervous system (CNS).

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!